Výsledky vyhledávání

Akademický článek

Autor: Zili Lin, Ziyi Wu, Yuhao Yuan, Wei Zhong, Wei Luo

Publikováno v: Frontiers in Pharmacology, Vol 14 (2023)

Background: Osteosarcoma (OS), a primary malignant bone tumor, confronts therapeutic challenges rooted in multidrug resistance. Comprehensive understanding of disease occurrence and progression is imperative for advancing treatment strategies. m7G mo

Externí odkaz: https://doaj.org/article/bb4c1e08d1a44a74855bc0fdd9b80b25

Zobrazit plný text záznamu

Akademický článek

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

Autor: Byung-Hyun Cha, Minjin Jung, Angela S. Kim, Victoria C. Lepak, Brett A. Colson, David A. Bull, Youngwook Won

Publikováno v: Journal of Biological Engineering, Vol 15, Iss 1, Pp 1-10 (2021)

Abstract Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physio

Externí odkaz: https://doaj.org/article/9b0e98c8331144218e05212cc539892d

Zobrazit plný text záznamu

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

Autor: Young-Wook Won, Byung-Hyun Cha, Victoria C. Lepak, Minjin Jung, David A. Bull, Angela S. Kim, Brett A. Colson

Publikováno v: Journal of Biological Engineering, Vol 15, Iss 1, Pp 1-10 (2021)
Journal of Biological Engineering

Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physiology and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f0c2ad31388846e2a28b8448ad4244
https://doaj.org/article/9b0e98c8331144218e05212cc539892d

Zobrazit plný text záznamu

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells

Autor: Zhenhua Liu, Yi Song, Shuai Hu, Jindong Sheng, Yu Fan, Tianjing Lv, Senmao Li, Cuijian Zhang, Jie Jin, Wei Yu

Publikováno v: Journal of Cellular and Molecular Medicine

Recent studies indicate mammalian target of rapamycin (mTOR) may play an important role in PCa progression and drug resistance. Here, we investigated the effects of a novel mTORC1/C2 dual inhibitor, AZD2014, on naive and docetaxel (Doc)‐pre‐treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59cc3b2d158ccbcd4504c33f05a4eeaa
https://doi.org/10.1111/jcmm.16155

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dual mTORC1/2 inhibitor AZD2014 inhibits proliferation of HCCLM3 cells through induction of autophagy

Autor: Hui LIAO, Xiao-Ping XU, Chen-Jie ZHOU, Jian-Min ZHANG, Ke-Bo ZHONG, Ding-Hua YANG

Publikováno v: Medical Journal of Chinese People's Liberation Army, Vol 45, Iss 5, Pp 509-512 (2020)

Objective To investigate the effect of mTORC1/2 inhibitor AZD2014 induced autophagy on cell proliferation in HCCLM3 cell lines in vitro. Methods HCCLM3 cells were cultured in the presence or absence of AZD2014 (100 nmol/L) or rapamycin (100 nmol/L) o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::ed445e898c7c35cd1f24b1d300ecab14
http://www.plamj.org/index.php/plamj/article/view/2217

Zobrazit plný text záznamu

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

Autor: Raphael J. Morscher, Pablo Berlanga, Caroline Brard, Ludovic Lacroix, Birgit Geoerger, Nicolas André, Souad Nebchi, Gaëlle Pierron, Nadège Corradini, Gilles Vassal, G Schleiermacher, Lynley V. Marshall, Peter G. Mortimer, Emilie De Carli, Xavier Paoletti, Isabelle Aerts, Jonathan Rubino

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩

International audience; Aim: Arms E and F of the AcSé-ESMART phase I/II platform trial aimed to define the recommended dose and preliminary activity of the dual mTORC1/2 inhibitor vistusertib as monotherapy and with topotecan-temozolomide in a molec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a7dc4b095aacabf3e9c654b9c35db8
https://pubmed.ncbi.nlm.nih.gov/34543871

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání